10rx vs GoodRx
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
10rx
Best for budget-focused patients who want low-cost compounded GLP-1 with NAD+ and sermorelin add-onsStarting at $99.67/mo
GoodRx
Best for self-pay brand-name Foundayo and Zepbound KwikPen at retail pharmaciesStarting at $149/mo
Side-by-Side Comparison
| Feature | 10rx | GoodRx |
|---|---|---|
| Overall Score | 7.0/10 | ✓8.4/10 |
| Starting Price | ✓$99.67/mo | $149/mo |
| Editorial Rating | 3.5 ★ /5 | ✓4.2 ★ /5 |
| Features | ✓8 features | 6 features |
| States Available | 0 | ✓50 |
| Compounded | — | — |
| Brand Name | — | ✓ Yes |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
10rx
What we like
- Very low pricing — compounded semaglutide $99.67/month and tirzepatide $149.67/month
- Free online health quiz with board-certified telehealth doctors reviewing eligibility
- Offers NAD+ and sermorelin alongside GLP-1, for energy and muscle recovery
- Says it ships to all 50 states with discreet delivery from licensed pharmacy partners
Watch-outs
- Doesn't publish its legal operating entity, so accountability is hard to verify
- Pharmacy partners are described as licensed but none are named
- No terms-of-service page is posted, and FAQ answers load only via script
- Compounded semaglutide and tirzepatide only — no brand-name or oral options
- No LegitScript or third-party accreditation is shown on the site
GoodRx
What we like
- $149/month self-pay for brand-name Foundayo (orforglipron) — matches the lowest cash price at launch, far below typical retail
- $299/month self-pay for Zepbound KwikPen — well under Lilly's typical cash list price
- Honored at 70,000+ US pharmacies — the largest retail redemption network of any GLP-1 channel we cover
- No membership fee — bring your own prescription and present the discount card at the pharmacy counter
- Brand-name FDA-approved medication, not compounded
- Manufacturer-direct pricing — Lilly delivers the discount through GoodRx, not a third-party negotiation
- GoodRx Care telehealth offers GLP-1 prescriptions ($39–$70 per visit, $19 with Gold) — one-stop for script plus card
Watch-outs
- Requires a valid prescription — GoodRx is a discount card, not a prescriber; you still need a clinician to write the script
- Self-pay only — does not apply toward insurance benefits or deductibles
- Headline price applies to the lowest Foundayo dose; higher doses may cost more
- No compounded GLP-1 options — not the channel for compounded semaglutide or tirzepatide
- Pricing can change as Lilly's manufacturer coupon program evolves
Our Verdict
GoodRx edges out 10rx with a higher overall score of 8.4/10 and is particularly strong for self-pay brand-name Foundayo and Zepbound KwikPen at retail pharmacies. 10rx remains a solid alternative, especially if you're looking for budget-focused patients who want low-cost compounded GLP-1 with NAD+ and sermorelin add-ons.
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Related comparisons
Continue exploring 10rx and GoodRx head-to-heads in the same category.
- 10rx vs CoreAge Rx
- 10rx vs TrimRx
- 10rx vs Amazon One Medical
- GoodRx vs NovoCare Pharmacy
- GoodRx vs Vytora Health
- GoodRx vs Enhance MD
Or see the full category ranking.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.